CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7044 result(s)

CADTH Drug Reimbursement Reviews

Published on: October 29, 2020
Result type: General Content

Once Health Canada has approved a drug for use in Canada, the country’s public drug programs and cancer agencies must decide if the drug will be eligible for public reimbursement. The CADTH drug reimbursement review process plays an important role in their decision-making processes. Through our review process, CADTH conducts thorough and object...

COVID-19 Update

Last Updated: November 2, 2020
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 evidence portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and growing state of the international scientific evidence...

ofatumumab (TBC)

Last Updated: October 19, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ofatumumab
Indications: For the treatment of Relapsing Multiple Sclerosis (RMS).

  • Brand Name: TBC
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-0000
  • Project Status: Active
  • Submission Type: Initial